The antibody was purified by affinity chromatography, and conjugated with Pacific Blue™ under optimal conditions. The solution is free of unconjugated Pacific Blue™ and unconjugated antibody.
Concentration:
0.5 mg/ml
Storage & Handling:
The antibody solution should be stored undiluted at 4°C and protected from prolonged exposure to light. Do not freeze.
Application:
FC - Quality tested
Recommended Usage:
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining, the suggested use of this reagent is ≤ 1.0 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
Human peripheral blood lymphocytes stained with CD3 (UCHT1) PE/Cy5 and TG1/CXCR3 Pacific Blue™
Description:
CXCR3 highly expressed by T lymphocytes (Th1),natural killer cells (NK cells), dendritic cells, mast cells, alveolar macrophages, eosinophils, and human airway epithelial cells. CXCR3 ligands require IFN- for their expression and are localized to sites of inflammation; therefore, CXCR3 is important for effector lymphocyte recruitment into inflamed tissue such as chronically inflamed human liver, Chrohns disease, rheumatoid arthritis, multiple sclerosis, and inflammatory skin diseases.
Other Names:
G protein-coupled receptor 9, GRP9, CD183 antigen, CD183, CXCR3
Structure:
CXC-chemokine receptor, G protein-coupled receptor, 7 transmembrane receptor
Distribution:
IL-2 activated T cells, Th1, natural killer cells (NK cells), dendritic cells, mast cells, alveolar macrophages, eosinophils, and human airway epithelial cells
Function:
CXCR3 is important for effector lymphocyte recruitment into inflamed tissues
Ligand Receptor:
CXCR3 ligands are the chemokines CXCL9, CXCL10 and CXCL11
Interaction:
CXCR3 promotes adhesion of effector T cells to endothelium and drives transendothelial migration
Antigen References:
1. Loetscher M, et al., 1996. J Exp Med. 184:963-969. 2. Cole KE, et al., 1998. J Exp Med 187:2009-2021. 3. Aksoy MO, et al., 2006. Am J Physiol Lung Cell Mol Physiol 290: L909-L918. 4. Curbishley SM, et al,. 2005. Am J Pathol. 167:887-899. 5. Turner JE, et al ., 2007. Min Rev Med Chem 7:1089-1096. 6. Wenzel J, et al., 2008. J Invest Dermatol 128:67-78.
